PharmaCyte Biotech Inc (PMCB)

[purplehp]

Maybe I could post a link, yes.

So here is what Austrianova has been doing (for themselves and PMCB)

2018 - not sure, perfumes? Hair regrowth encapsulation? MSC-Encap? They update their fb page
http://www.lorealinnovationrunway.sg/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470686/

Ah well this last one is tricky. Austrianova posted about a stem cell partner in Aug. 2017. I have found one document which I think I shouldn't have found. It concerns Tithon Biotech Inc. So it either is a big secret or the deal is off. Let your fantasy run free.

https://tbitherapy.com/wp-content/uploads/2017/10/Tithon-Encapsulated-Mesenchyme-Stem-Cells.pdf

By using Austrianova’s well tested cell encapsulation technology
along with its experience in the area of encapsulation, in combination with
Tithon’s unique and proprietary immortalized adipose-derived mesenchyme stem cell product and
Tithon’s expertise and clinical experience in the stem cell industry, an off-the-shelf encapsulated stem cell product is in the works(“MSC-Encap(s)”).

Vasilis Paspaliaris as the CEO of
http://tithonbiotech.com/

The science behind this:
https://onlinelibrary.wiley.com/doi/abs/10.1002/jbm.a.35493
Full article here (don't know if these are legal uploads though):
https://docksci.com/inefficiency-in-macromolecular-transport-of-scs-based-microcapsules-affects-viab_5a4dd1a6d64ab2e004034082.html

To our knowledge, SCS-based microcapsule systems
have been mainly employed for the encapsulation of estab-
lished cell lines. However, the use of cell lines may be a
concern for the regulatory bodies when designing clinical
trials, in particular, immortalized cells that are able to form
tumors in vivo. For this reason, our interest focused on the
encapsulation of primary human cells such as MSCs, which
are of interest in many clinical applications. In the present
work, we have also investigated the behavior of other pri-
mary cell types such as human fibroblasts, and two cell
lines including hMSC-TERT cells and HEK293 cells, for com-
parative purposes.
Our results showed that the viability of primary cells
such as hMSCs and hFibroblasts encapsulated in this device
was limited compared to the performance of established
cell lines such as hMSC-TERT and HEK293 cells. Similarly,
hMSC had a reduced metabolic activity over the 14 days of
culture compared to hMSC-TERT cells. This observation
suggests that primary cells may find some elements of
microcapsule environment detrimental whereas their im-
mortalized counterpart is able to survive in these condi-
tions. Nevertheless, we found that microcapsule material
was not cytotoxic to primary hMSCs by either direct or indi-
rect contact.
Intriguingly, we found that hMSC-TERT cells had exten-
sive proliferation by day 14, and cells occupied about 50%
of the microcapsule inner membrane. Uncontrolled prolifer-
ation from immortalized cells could be worrisome from a
safety point of view.

Anyway.

2017 - in service of PMCB
examining cell properties to select best cell for the homogeneous cell line
testing alternatives to fetal calf serum since now forbidden
testing alternative mediums since ours currently unavailable
transferring know-how to Eurofins
testing R&D cell bank for shelf life
Sources: CC and PRs, sorry, don't have video recordings or access to their database

2012 - 2016 - check PRs and publications
http://austrianova.com/news/encapsulation-cell-in-a-box-press-releases.html
http://austrianova.com/encapsulation-cell-in-a-box-publications.html


You're welcome!

I'll post a bit later the links for the improved CiaB.